Affymax lifted by EU acceptance of peginesatide filing
This article was originally published in Scrip
Executive Summary
The formal acceptance by the European Medicines Agency of a marketing application for Affymax's peginesatide has triggered a $5 million milestone payment by global licensee Takeda and provided a boost to the US firm's stock.